Aims & Scope
Current Cancer Drug Targets aims to cover all the latest and outstanding developments
in full spectrum of cancer drug discovery and development, including but not
limited to cellular and molecular biology, genomics, proteomics, metabolomics,
medicinal chemistry, pharmacology, toxicology, and biochemistry of contemporary
molecular drug targets involved in cancer, e.g. disease specific proteins,
receptors, enzymes and genes.
Current Cancer Drug Targets publishes original research articles,
letters/commentary/perspectives, reviews / mini-reviews, drug clinical trial
studies and guest edited thematic issues written by leaders in the field
covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and
validation of novel drug targets for human anticancer drug discovery continues
to grow, this journal has become essential reading for all biomedical and
pharmaceutical scientists involved in drug discovery and development. Its scope
covers publications related to prevention, diagnosis and treatment of all types
of human cancers in various of basic and translational researches, including
cancer etiology, signal transduction, biomarker, chemotherapy, hormone therapy,
gene therapy, immunotherapy, radiotherapy, immunotherapy and combination
therapy, stem cell, tumor environment, metabolism emphasizing on advanced
mechanistic investigations.
